Sector News

Lilly starts phase 3 test of COVID-19 antibody in nursing homes

August 4, 2020
Life sciences

Eli Lilly has started a phase 3 trial to evaluate whether its antibody LY-CoV555 stops the residents of nursing homes from developing COVID-19.

Lilly has created customized mobile research units to run the clinical trial at nursing homes as the long-term care facilities lack experience running studies.

More than 40% of all U.S. deaths from COVID-19 involve nursing home residents and staff, according to a New York Times analysis, despite just 8% of cases occurring in such facilities. In 20 states, nursing homes account for more than half of all COVID-19 deaths. Eighty-two percent of COVID-19 deaths in New Hampshire involve nursing homes.

The disproportionate burden borne by nursing homes suggests immunizing residents and workers at long-term care facilities against the pandemic SARS-CoV-2 virus could significantly reduce the death toll. However, the limited response of seniors to vaccines may make it hard to provide protection.

Antibodies provide an alternative, and in seniors potentially more effective way, to protect people against the coronavirus. Infusing anti-SARS-CoV-2 into people at risk of exposure to the virus could provide temporary protection against the pandemic pathogen.

Lilly is putting that idea to the test. Having started the first clinical trial of a potential COVID-19 antibody two months ago, Lilly has now initiated a phase 3 trial to assess the prophylactic potential of LY-CoV555.

The trial will enroll up to 2,400 residents and staff at nursing homes that have recently had a case of COVID-19. By targeting facilities with confirmed cases of COVID-19, Lilly stands to accelerate the task of showing whether LY-CoV555 protects against the virus. Lilly will assess the effect of a single dose of LY-CoV555 on the rate of infection and complications of COVID-19 for four weeks and eight weeks, respectively.

Lilly, working with the National Institute of Allergy and Infectious Diseases, the COVID-19 Prevention Network and nursing home networks, has sought to counter the challenges of running clinical trials in long-term care facilities. Specifically, Lilly has customized recreational vehicles to support mobile labs and the preparation of clinical trial materials. A trailer truck will deliver the clinical trial supplies required to set up on-site infusion clinics. Lilly will use the fleet to address outbreaks across the U.S.

The mobile research units are needed as long-term care facilities rarely run clinical trials and, as such, lack the infrastructure and expertise to execute the study. Under normal circumstances, participants may travel to clinical trial sites for treatment and monitoring, but that is potentially unsafe today.

Other companies are assessing anti-SARS-CoV-2 antibodies in more conventional clinical trials. Last month, Regeneron began a phase 3 trial to test the prophylactic power of its REGN-COV2 antibody cocktail in uninfected people who have recently been exposed to COVID-19 patients. The protocol of that trial, which is enrolling at 100 U.S. study centers, specifically excludes nursing home residents.

In finding a way to evaluate LY-CoV555 at nursing homes, Lilly has positioned itself to carve out a niche in the busy anti-SARS-CoV-2 antibody space by serving a population that particularly needs the protection it may be able to provide.

By: Nick Paul Taylor

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend